Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, gives an overview of the use of MB-106, a 3rd generation CD20-targeted chimeric antigen receptor (CAR) T-cell therapy, for the treatment of B-cell non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia (CLL). A Phase I/II trial (NCT03277729) investigating the safety and efficacy of MB-106 for high-risk B-NHL and CLL has reported a complete response rate of 82% amongst 11 patients with follicular lymphoma. No grade three or four cytokine release syndrome has been reported in patients with follicular lymphoma. A patient with high-risk CLL had a complete response to MB-106 with no detectable measurable residual disease (MRD). Dr Shadman comments on these findings, highlighting MB-106’s promising safety profile. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.